TY - JOUR
KW - opioid use disorder
KW - Project ECHO
KW - buprenorphine
KW - full agonist opioid prescribing
KW - primary care
AU - A. Gadomski
AU - J. Anderson
AU - Y. K. Chung
AU - N. Krupa
AU - P. Jenkins
A1 - 
AB - Background: While primary care clinicians are being trained to use buprenorphine for the treatment of Opioid Use Disorder (OUD) in order to increase access to addiction treatment, it is not known what impact such training and subsequent experience treating patients with OUD has on full agonist opioid prescribing. Methods: This retrospective cohort study compares the full agonist opioid prescribing patterns of Drug Addiction Treatment Act (DATA)-waivered ("X-waivered") primary care clinicians to non-trained, non-waivered clinicians in a rural health network. X-waivered clinicians also received Project ECHO training and telementoring support for one year. Using prescriber data generated by an electronic medical record system, opioid prescribing and morphine milligram equivalents (MME) per day per patient were calculated. A between-group analysis was used to compare the study groups six months pre-versus post-training. Results: Although the mean number of full agonist opioid prescriptions per clinician and per 100 patient encounters decreased among all clinicians, there was no change in full agonist opioid prescribing MME. As expected, buprenorphine prescribing by X-waivered, trained clinicians increased significantly post-training. Conclusions: X-waivers plus Project ECHO support for the treatment of OUD using buprenorphine had no effect on full agonist opioid prescribing by primary care clinicians.
AD - Bassett Medical Center, Bassett Research Institute, Cooperstown, NY, USA.; Department of Medicine, Bassett Medical Center, Cooperstown, NY, USA.; College of Medicine, SUNY Upstate Medical University, Syracuse, NY, USA.; Bassett Medical Center, Bassett Research Institute, Cooperstown, NY, USA.; Bassett Medical Center, Bassett Research Institute, Cooperstown, NY, USA.
BT - Substance abuse
C5 - Education & Workforce; Healthcare Disparities; HIT & Telehealth; Opioids & Substance Use
CY - United States
DO - 10.1080/08897077.2020.1736709
JF - Substance abuse
LA - eng
M1 - Journal Article
N2 - Background: While primary care clinicians are being trained to use buprenorphine for the treatment of Opioid Use Disorder (OUD) in order to increase access to addiction treatment, it is not known what impact such training and subsequent experience treating patients with OUD has on full agonist opioid prescribing. Methods: This retrospective cohort study compares the full agonist opioid prescribing patterns of Drug Addiction Treatment Act (DATA)-waivered ("X-waivered") primary care clinicians to non-trained, non-waivered clinicians in a rural health network. X-waivered clinicians also received Project ECHO training and telementoring support for one year. Using prescriber data generated by an electronic medical record system, opioid prescribing and morphine milligram equivalents (MME) per day per patient were calculated. A between-group analysis was used to compare the study groups six months pre-versus post-training. Results: Although the mean number of full agonist opioid prescriptions per clinician and per 100 patient encounters decreased among all clinicians, there was no change in full agonist opioid prescribing MME. As expected, buprenorphine prescribing by X-waivered, trained clinicians increased significantly post-training. Conclusions: X-waivers plus Project ECHO support for the treatment of OUD using buprenorphine had no effect on full agonist opioid prescribing by primary care clinicians.
PP - United States
PY - 2020
SN - 1547-0164; 0889-7077
SP - 1
EP - 7
EP - 
T1 - Full agonist opioid prescribing by primary care clinicians after buprenorphine training
T2 - Substance abuse
TI - Full agonist opioid prescribing by primary care clinicians after buprenorphine training
U1 - Education & Workforce; Healthcare Disparities; HIT & Telehealth; Opioids & Substance Use
U2 - 32150525
U3 - 10.1080/08897077.2020.1736709
VO - 1547-0164; 0889-7077
Y1 - 2020
Y2 - Mar 9
ER -